Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
No open-market purchase by an insider of Labcorp was filed in the last 90 days. The latest on record was on Sep 7, 2022.
How often do Labcorp insiders buy and sell shares?
Since 2006, Labcorp insiders reported 9 open-market purchases and 2,187 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2022.
Who is selling Labcorp stock?
In the last 90 days, 4 insiders of Labcorp (LH) reported 4 open-market sales worth $1.38M in total on SEC Form 4. The largest seller by value was Brian J Caveney, with $744K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade LH?
Yes. Members of Congress disclosed 9 trades in Labcorp (LH) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. April McClain Delaney (MD06), Sen. Alan Armstrong.
When does Labcorp report its next results?
Labcorp's next results are expected on Feb 15, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+40.4% (+$105.66) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $261.47 on Nov 20, 2025 to $367.13 on Nov 20, 2026 (+40.4%). Disclosed in this range: 8 insider trades, 15 pre-arranged insider sales, 8 Congress trades, and 42 13F position changes for 4 quarters ending in it.
$200$250$300$400$367.13
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 31 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Services company based in Burlington, North Carolina.
Last 12 months
+40.4%
S&P 500 +5.7% over the same dates
Market value
$29.8B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 2.54M shares sold short (3.1% of shares outstanding), −0.5% vs the previous count, 3.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Latest results: quarter ending Sep 30, 2026
Revenue
$3.81B
+6.9% vs the same quarter a year earlier
Free cash flow, last 12 months
$1.29B
This quarter $412M, a year earlier $281M
Net debt
$5.59B
Debt $5.85B, cash $262M, at Sep 30, 2026
Net income, last 12 months
$1B
Operating profit covers interest 6.52x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 28, 2026.
Insiders of Labcorp reported 9 open-market purchases and 2,187 sales since 2006; purchases in 4 different years, most recently 2022.
Year
Bought
Sold
2026
—
$11.8M23×23 trades
2025
—
$15.1M23×23 trades
2024
—
$25.5M32×32 trades
2023
—
$5.9M12×12 trades
2022
$943K5×5 trades
$16.2M21×21 trades
2021
—
$5.17M18×18 trades
2020
$99K2×2 trades
$11.2M15×15 trades
2019
—
$12.6M18×18 trades
2018
—
$34.7M26×26 trades
2017
—
$37.6M24×24 trades
2016
—
$32.1M23×23 trades
2015
—
$27.7M39×39 trades
2014
—
$37.4M30×30 trades
2013
—
$53M34×34 trades
2012
—
$31.2M24×24 trades
2011
—
$23.6M25×25 trades
2010
$453K1×1 trade
$33.1M34×34 trades
2009
—
$2.25M12×12 trades
2008
$24K1×1 trade
$63.9M743×743 trades
2007
—
$60.1M493×493 trades
2006
—
$52.5M518×518 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
“(the “Company”) of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026.”
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Since Nov 19, 2025, LH is up 40.9% and the index fund is up 4.1%: 37 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much LH moves
A usual day
±0.9%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
2.3%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−4.5%Apr 10, 2026
Largest one-day rise
+8.8%Oct 28, 2026
Deepest fall of the year
−13.6%From the close of Feb 11, 2026 to May 15, 2026.
Days of 5% or more
1Out of 252 sessions, in either direction.
Beta 0.3(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Last 30 days
Written by software from the filings listed below · Nov 21, 2026
Insiders. In the 30 days to Nov 21, 2026, insiders of Labcorp filed 0 open-market purchases and 4 open-market sales (about $1.38M, in 4 filings, by 4 people). One Form 4 can list many transactions. In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales. (Labcorp on OQRO)
Funds and stakes. Fund 13F filings recorded in the 30 days show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for LH on the settlement date of Oct 30, 2026 was 2,544,414 shares (-0.52% on the previous report), about 3.01 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 144 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Labcorp filed a Form 8-K on Oct 28, 2026 (Item 2.02) that OQRO classes as: reported its results. Its announcing sentence reads: "Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year financial guidance."
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 30 days to Nov 21, 2026, insiders of Labcorp filed 0 open-market purchases and 4 open-market sales (about $1.38M, in 4 filings, by 4 people). One Form 4 can list many transactions.
In the 30 days before that, they filed 0 open-market purchases and 0 open-market sales.
The largest sale: Brian J Caveney, EVP, Pres of BLS, CMO & CSO, about $744K, filed Nov 12, 2026.
Funds and stakes
Fund 13F filings recorded in the 30 days show 0 new or larger positions and 1 smaller or closed position. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for LH on the settlement date of Oct 30, 2026 was 2,544,414 shares (-0.52% on the previous report), about 3.01 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 144 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $18.3M for its principal executive officer, and an average of $4.22M for the other named executive officers.
Company reports, price and press
Labcorp filed a Form 8-K on Oct 28, 2026 (Item 2.02) that OQRO classes as: reported its results.
Its announcing sentence reads: "Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2026 and updated its full-year financial guidance."
Press coverage listed by Finnhub: "If You Invested $100 In Labcorp Holdings Stock 20 Years Ago, You Would Have This Much Today" (Benzinga, Nov 19, 2026).
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Labcorp filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 23 open-market sales (about $11.8M, in 22 filings, by 10 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 27 open-market sales (about $19.2M, in 26 filings). (Labcorp on OQRO)
Congress. Members of Congress filed 9 disclosures on Labcorp in the 12 months to Nov 19, 2026: 5 purchases and 4 sales, by 2 members. In the 12 months before that: 11 disclosures. The largest range: Rep. April McClain Delaney (MD06), $100,001 to $250,000, filed Sep 9, 2026.
Funds and stakes. Fund 13F filings recorded in the 12 months show 17 new or larger positions and 25 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings. FINRA short interest for LH on the settlement date of Oct 30, 2026 was 2,544,414 shares (-0.52% on the previous report), about 3.01 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 144 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. Labcorp filed a Form 8-K on Aug 14, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member. The company's own opening sentence of that report reads: "On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the 'Company') of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4,..."
Who holds it. 1,043 funds reported a stake in Labcorp in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (8.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.8% of the value reported), VICTORY CAPITAL MANAGEMENT INC (6.1% of the value reported).
Attention. The English Wikipedia article on Labcorp was read about 141 times a day in the 7 days to Nov 18, 2026, against a usual 150 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Labcorp filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 23 open-market sales (about $11.8M, in 22 filings, by 10 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 27 open-market sales (about $19.2M, in 26 filings).
The largest sale: Adam H Schechter, President & CEO, about $2.44M, filed Mar 5, 2026.
Congress
Members of Congress filed 9 disclosures on Labcorp in the 12 months to Nov 19, 2026: 5 purchases and 4 sales, by 2 members. In the 12 months before that: 11 disclosures.
The largest range: Rep. April McClain Delaney (MD06), $100,001 to $250,000, filed Sep 9, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 17 new or larger positions and 25 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Contracts, lobbying and filings
FINRA short interest for LH on the settlement date of Oct 30, 2026 was 2,544,414 shares (-0.52% on the previous report), about 3.01 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: none on record; the largest that shrank: Bridgewater Associates (reduced, 144 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $18.3M for its principal executive officer, and an average of $4.22M for the other named executive officers.
Company reports, price and press
Press coverage listed by Finnhub: "OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "Labcorp Collaborates With Grupo Fleury To Expand Clinical Trial Operations In Brazil" (Benzinga, Nov 17, 2026).
LH closed at $367.13 on Nov 20, 2026, the last session on or before the end of the period.
From Oct 21, 2026 to Nov 20, 2026, the close moved from $323.75 to $367.13, a change of +13.4%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Labcorp filed a Form 8-K on Aug 14, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the 'Company') of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4,..."
Labcorp filed a Form 8-K on Feb 9, 2026 (Items 5.02, 7.01) that OQRO classes as: changed a top executive or board member, and shared information with investors.
The company's own opening sentence of that report reads: "Labcorp Holdings Inc. (the 'Company') today announced that on February 6, 2026, the Company’s Board of Directors (the 'Board') appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026."
Labcorp filed a Form 8-K on Dec 15, 2025 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On December 9, 2025, Mark Schroeder, the Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer of Labcorp Holdings Inc. (the 'Company'), notified the Company of his intention to retire, eff..."
Press coverage listed by Finnhub: "OTraces Selects Labcorp to Perform Biomarker Testing for Florida Department of Health–Funded Prostate Cancer Study" (Yahoo, Nov 18, 2026).
Press coverage listed by Finnhub: "Labcorp Collaborates With Grupo Fleury To Expand Clinical Trial Operations In Brazil" (Benzinga, Nov 17, 2026).
Press coverage listed by Finnhub: "Labcorp’s Lab Growth Surges as $125 Million Reimbursement Risk Looms" (Yahoo, Nov 13, 2026).
LH closed at $370.78 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $318.83 to $370.78, a change of +16.3%.
Who holds it
1,043 funds reported a stake in Labcorp in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (8.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (6.8% of the value reported), VICTORY CAPITAL MANAGEMENT INC (6.1% of the value reported).
Attention
The English Wikipedia article on Labcorp was read about 141 times a day in the 7 days to Nov 18, 2026, against a usual 150 a day over the 90 days before. Reads measure attention, not buying or selling.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
People read Labcorp's Wikipedia article about 120 times a day over the last week, close to the 150 on a usual day of the three months before.
May 16, 2026Busiest day: 280 views on Jun 8, 2026Nov 21, 2026
Views of the article Labcorp, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Risk factors in the annual report
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 25, 2025. Read the filing
No longer listed (2 headings from the year before)
The spin-off of Fortrea may not achieve the intended results.
Any cybersecurity incidents affecting the information technology systems of third parties that provide services to the Company could have a material adverse effect on the Company's operations.
Legal proceedings (Item 3)
See Note 15 Commitments and Contingencies to the Consolidated Financial Statements.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
When insiders usually buy
Last results
Oct 28, 2026
Within the 30 days after it, until Nov 27, 2026
Next results, expected
Feb 15, 2027
Purchases after results
Not enough history
From Labcorp's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Labcorp's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 24, 2026. Read the filing
By business segment
Diagnostics$10.9B78%
+7.2% on the year before ($10.1B). Operating income $1.78B, a 16% margin
Biopharma Laboratory Services$3.1B22%
+6.0% on the year before ($2.92B). Operating income $499M, a 16% margin
Total revenue$14B+7.2%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 7,000 words.
From “GENERAL (dollars in millions)”, in the company's words
For the year ended December 31, 2025, the Company’s revenues were $13,951.7, an increase of 7.2% from $13,008.9 for the corresponding period in 2024. The 7.2% increase in revenues for the year ended December 31, 2025, as compared to the corresponding period in 2024, was primarily due to organic revenue of 4.4%, acquisitions, net of divestitures of 2.5%, and favorable foreign currency translation of 0.4%. The Company defines organic growth as the increase in revenue excluding the year over year impact of acquisitions, divestitures, and currency. Acquisition and divestiture impact is considered for a 12-month period following the close of each transaction. On June 30, 2023, the Company completed the Spin-off.
What the section covers (32 headings)
GENERAL (dollars in millions)
RESULTS OF OPERATIONS (dollars in millions)
Revenues
Cost of Revenues
Selling, General, and Administrative Expenses
Amortization of Intangibles and Other Assets
Goodwill and Other Asset Impairments
Restructuring and Other Charges
Interest Expense
Equity Method Loss, Net
Other, Net
Provision for Income Taxes
Results of Operations by Segment
LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions, except per share amounts)
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Short sale volume: 49.7% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 56.0%. FINRA daily files, to Nov 20, 2026.
Fails to deliver: 9,779 shares (about $3.17M) were not delivered on time for settlement on Oct 22, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 44.5% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (33.4% on ATS, 11.1% with other brokers), above its 26-week average of 42.3%. Weeks of Oct 5 to Oct 30, 2026.
Week of May 4ATSOther off-exchangeFull height = all shares tradedWeek of Oct 26
Largest ATS: UBS ATS (14.0%), INTELLIGENT CROSS LLC (10.0%), SIGMA X2 (9.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.